US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
SV

SVE.WA

$2.90
Sharia status
NOT COMPLIANT
Per In-house ratio engine · assessed 2026-08-28
HTR non-permissible income 0.03%
🕌Open research, not a fatwa — verify with your own scholar.
Trade setup SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.

Synthaverse S.A. (SVE.WA) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-28). See the full ratio breakdown and business-activity screen below for the reasoning.

⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.

Market & analysts
Institutional own.
6.8%
of shares
NON-COMPLIANT
Sharia compliance
0.03%
Non-permissible income — HTR, from filings (2025-12-31)
6.8%
Institutional ownership

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2025-12-31. SVE.WA files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.

Business activity: cleared (no excluded categories detected)

AAOIFI Fail

RatioValueThresholdResult
Interest-bearing debt 51.65% 30.00% Fail
Interest-bearing investments 1.02% 30.00% Pass
Non-permissible income 0.03% 5.00% Pass

Usmani Pass

RatioValueThresholdResult
Interest-bearing debt 29.41% 33.00% Pass
Interest-bearing investments 0.55% 33.00% Pass
Non-liquid assets 92.46% at least 20.00% Pass
Non-permissible income 0.03% 5.00% Pass

MSCI Pass

RatioValueThresholdResult
Interest-bearing debt 27.83% 33.33% Pass
Cash + interest-bearing securities 0.55% 33.33% Pass
Accounts receivable 7.54% 33.33% Pass
Non-permissible income 0.03% 5.00% Pass

FTSE Pass

RatioValueThresholdResult
Interest-bearing debt 27.83% 33.33% Pass
Cash + interest-bearing securities 0.55% 33.33% Pass
Accounts receivable 7.54% 50.00% Pass
Non-permissible income 0.03% 5.00% Pass

Dow Jones Islamic Market Fail

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 38.19% 33.00% Fail
Cash + interest-bearing securities 0.75% 33.00% Pass
Accounts receivable 9.59% 33.00% Pass
Non-permissible income 0.03% 5.00% Pass

S&P Shariah Fail

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 36.79% 33.00% Fail
Cash + interest-bearing securities 0.73% 49.00% Pass
Accounts receivable 9.24% 49.00% Pass
Non-permissible income 0.03% 5.00% Pass

MSCI M-Series Fail

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 36.79% 33.33% Fail
Cash + interest-bearing securities 0.73% 33.33% Pass
Accounts receivable 9.97% 49.00% Pass
Non-permissible income 0.03% 5.00% Pass

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

4.504.043.573.112.642025-09-112026-03-162026-09-11

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
2.81
S2
2.87
S1
2.91
PIVOT
2.97
R1
3.01
R2
3.07
R3
3.11

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

7-day expected range
2.80574 3.17426
±6.16% from 2.99, made 2026-09-03 · resolves 2026-09-10
STRONG BUY
from 19 indicators
Not enough resolved predictions yet — 0 of 10 needed before we publish an accuracy figure. 22052 forecast(s) are currently open and will be scored automatically when their horizon expires.

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

Technical Summary

STRONG SELL
19 indicators
OscillatorsSELL
2 buy · 2 neutral · 3 sell
Moving averagesSTRONG SELL
1 buy · 0 neutral · 11 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)43.80NEUTRAL
Stochastic %K (14)0.00BUY
CCI (20)-61.93NEUTRAL
Williams %R (14)-100.00BUY
MACD (12,26,9)-0.01SELL
ROC (10)-3.97SELL
Momentum (10)-0.12SELL
EMA (10)2.97SELL
SMA (10)2.98SELL
EMA (20)2.96SELL
SMA (20)2.97SELL
EMA (30)2.95SELL
SMA (30)2.97SELL
EMA (50)2.94SELL
SMA (50)2.89BUY
EMA (100)3.03SELL
SMA (100)2.93SELL
EMA (200)3.38SELL
SMA (200)3.36SELL

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

About Synthaverse S.A.

Healthcare · Biotechnology

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents for use in oncology, gynecology, hematology, immunology, and related therapeutic areas in Poland, the rest of the European Union, and internationally. The company operates through the BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anti-D 50 and GAMMA anti-D 150, which are human anti-rh0(d) immunoglobulin products used in the prevention of maternal-fetal conflict in terms of the D antigen with the Rh system; GAMMA anty HBs 200 medications for use in passive prophylaxis hepatitis B virus; and BCG 10 tuberculosis vaccines. It also provides Distreptaza, a medication for chronic ovarian inflammation and hemorrhoidal disease; LAKCID, which is a lactobacillus probiotic drug; and pseudocholinoesteraza, which is a laboratory reagent. In addition, the company engages in the contract production of injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, and suppository forms of drugs. The company was formerly known as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. and changed its name to Synthaverse S.A. in July 2023. Synthaverse S.A. was founded in 1944 and is headquartered in Lublin, Poland.

synthaverse.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

SMC — Top Down

Not enough price history yet for a smart-money structure read on any timeframe.

Momentum & Volume

Peer Movement

Peer movement computing — it will appear here on its own.

Insider Activity (90d)

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

NEUTRAL   report date 2026-09-01 · Asset managers net 934180 (-19048)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.

Tell us what's working, what's confusing, or what you want to see next — read by a real person, not a form that goes nowhere.